MetaMask Surpasses 21 Million MAUs as ConsenSys Raises $200 Million to Make Web3 Universally Easy to Use, Access, and Build On
Today, ConsenSys announced the close of a $200 million USD financing round, bringing its valuation to $3.2 billion USD. New investors Marshall Wace, Third Point, ParaFi Capital, and Think Investments contributed to the round alongside new partners that include Dragonfly Capital, Electric Capital, Spartan Group, DeFiance Capital, Animoca Brands, Coinbase Ventures, and HSBC. Sullivan & Cromwell LLP acted as ConsenSys’ legal advisor in this transaction.
ConsenSys’ mission is to unlock the collaborative power of communities by making Web3 universally easy to use, access, and build on. MetaMask is the primary way a global user base of approximately 21 million monthly active users — a 38x increase from 2020 — interacts with a universe of approximately 3,700 unique Web3 applications. Web3 allows creators to capture the true value of their work and communities to organize in real time, largely unfettered by borders. These applications include NFT marketplaces, play-to-earn games, decentralized autonomous organizations (DAOs), decentralized finance (DeFi) applications, and metaverse worlds.
As the leading self-custodial wallet, MetaMask acts as a digital authority manager for Web3 — only permitting websites and apps to access data that a user consents to. MetaMask’s in-app swap feature has enabled more than $10 billion USD in peer-to-peer token swapping. Additionally, MetaMask now supports Ethereum-compatible Layer 2 networks such as Polygon, Optimism, Arbitrum, zkSync, BSC, Celo, Avalanche, and NEAR/Aurora, which represents more than 90% of global smart contract network volume. An institution-compliant version of Metamask, MetaMask Institutional integrates custody and compliance solutions that enable organizations to access and engage in DeFi. ConsenSys is also ramping up its efforts to drive NFT adoption for artists, content creators, brands, rights owners, game publishers, and leagues.
ConsenSys’ developer tools and infrastructure are anchored by Infura, which is used by 350k developers, including MetaMask and leading DeFi and NFT platforms. Developers choose Infura because of its industry leading scale and performance, best-in-class documentation, and resources to help developers spend less time on infrastructure and more time building. ConsenSys is increasingly integrating its other products with Infura to support the entire development lifecycle, such as Truffle (4.7 million developers) for writing and testing smart contracts, Diligence for securing smart contracts with hands-on code audits and automated testing tools, and Customer Success for tech support. ConsenSys Quorum Blockchain Service offers a fully managed Ethereum blockchain service to enterprises. ConsenSys Quorum is already in use by 10 different Central Bank Digital Currency projects around the world. ConsenSys’ protocol and R&D engineers are main drivers of Ethereum’s upcoming merge which will bring the more energy efficient and scalable Proof of Stake consensus system to Ethereum.
Funding will support the rapid expansion of MetaMask and Infura’s industry leading products as well as the addition of 400 new roles across its products and services.
Joseph Lubin, Founder & CEO of ConsenSys and Co-creator of Ethereum said, “The Age of Silos and Trusted Third Parties (h/t @punk6529) is giving way to the Age of Community and Collaboration enabled by an automated, objective, trust foundation and a decentralized finance ecosystem. The paradigm shift to a world running on decentralized protocols is in full gear. The pace of adoption is now so rapid that we’ve more than doubled many of our core KPIs since this deal was struck over the summer. We are honored to partner with some of the top financial and strategic investors from both traditional and next generation economies to accelerate the realization of Web3. As our technology crosses into the mainstream, we are already seeing the transformation of how larger and larger cohorts of builders, users, artists, and enterprises live and work.”
Amit Rajpal, Partner and CEO Asia at Marshall Wace said, "We are excited to be investing in ConsenSys. The consumer, developer, and enterprise ecosystems for Defi and NFT applications are building exponentially and blockchain technology companies, like ConsenSys, which have multi-faceted technology offerings are in position to be the access point to this universe. We particularly look forward to working with Joe and his team to enhance their presence in the Asian region where adoption rates are rising rapidly."
Daniel S. Loeb, CEO and Founder of Third Point LLC said, “ConsenSys’ MetaMask wallet and other tools offer a unique platform for consumers, enterprises, and developers to engage, build, and create on the decentralized web. We are pleased to partner with ConsenSys to help unlock the unlimited potential of Web 3.0.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006028/en/
Contact information
Zara Gleasure
zara@cw8-communications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release
Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release
Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release
4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom